NCT06130566: An ongoing trial by Sanofi
This trial is ongoing. It must report results 1 month from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06130566 |
|---|---|
| Title | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Nov. 8, 2023 |
| Completion date | July 23, 2025 |
| Required reporting date | July 23, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | June 19, 2026 |
| Days late | None |